Thursday , January 28 2021

Florencia Gonzalez Lizraga researches Parkinson's and received a prize



Proud of her work, her team and the level of science made in Tucumán, Florencia Gonzalez Lizeraga He is grateful for the distinction he received from the Argentine Society for Biophysics, the institution of its most important type in Israel. He was awarded the Jorge Pons Hornos Prize after being selected among 350 works by scientists from all over the country. "This work is my doctoral thesis (she is going to be a doctor in biology). I am the first author of the work, but we discuss these issues as a team," she explains.

The Florence investigation was carried out at the Institute for Molecular and Mobile Medicine (Immca), which is dependent on UNT, the conch and the district health office, and is responsible for Rosanna Chin. The work also relies on the collaboration of UBA's Advanced Microscopy Center, which directs Lia Peterson. Yesterday was Florence when he spoke on the phone with La Gasta.

The basis for the young scientist's study is an antibiotic called dioxicyclin, which belongs to a group of tetracyclines. This antibiotic has the ability to interact with alpha-synuclein protein, responsible for the death of dopasinérgicas neurons (those that communicate with other neurons using dopamine). These are the neurons that die in people with Parkinson's disease.

But, doxycycline is not suitable for long term diseases such as neurodegenerative diseases because it can generate resistance to bacteria.

"The second part of the work is to find a drug called COL 3, which is also tetracycline, but genetically engineered so it has no antibiotic activity and therefore does not produce resistance, and it does an anti-inflammatory action and makes the alpha-synuclein protein non-toxic, dopano.

"In this way, Parkinson's disease stops … that is, it is not palliative care as well as current treatments," emphasizes Florence.

Of course, the study is still in the lab stage. In vitro and in vivo testing are done, but there is still a long way to go to the stage of clinical trials in humans. Nevertheless, this is certainly a great hope.

The second mention of the Hornes Poons Prize was also for Tucuman: Lucia is a country, For work on Alzheimer's disease.


Source link